US37185R4065 - ADR
GENETIC TECH LTD-SP ADR
NASDAQ:GENE (4/25/2024, 7:00:01 PM)
After market: 2.2 +0.02 (+0.92%)2.18
-0.07 (-3.11%)
Genetic Technologies Ltd. is a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 60 full-time employees. The firm offers predictive genetic testing and risk assessment tools. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its GeneType and EasyDNA brands. The firm operates through three segments: EasyDNA, AffinityDNA, and geneType / Corporate. The EasyDNA segment relates to EasyDNA branded test sales and expenses. The AffinityDNA segment relates to AffinityDNA branded test sales and expenses. The geneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. GeneType also offers integrated risk testing for a range of serious conditions. EasyDNA and AffinityDNA offer deoxyribonucleic acid (DNA) testing services.
GENETIC TECH LTD-SP ADR
60-66 Hanover St, Fitzroy
Melbourne VICTORIA 3065
P: 61394151135
CEO: Simon Morriss
Employees: 60
Website: https://www.gtglabs.com/
Genetic Technologies Announces Closing of $2 Million Registered Direct Offering...
Genetic Technologies Announces $2 Million Registered Direct Offering...
Here you can normally see the latest stock twits on GENE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: